Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
for B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
275 locations incl. Birmingham
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT03739814·Phase 2·Recruiting